Therapeutic benefit of pentoxifylline for Peyronie's disease

Payton, Sarah

doi:10.1038/nrurol.2010.53

Cited by 4 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is gaining acceptance as a conservative treatment for Peyronie’s disease, in which it inhibits TGF-β-mediated collagen deposition and fibrosis in the tunica albuginea [8,12,19]. Furthermore, a recent trial showed beneficial synergistic effects of coadministration of PTX and sildenafil on arterial ED [20].…”

Section: Discussionmentioning

confidence: 99%

Pentoxifylline Promotes Recovery of Erectile Function in a Rat Model of Postprostatectomy Erectile Dysfunction

et al. 2011

View full text Add to dashboard Cite

Background-Cavernous nerve (CN) injury during radical prostatectomy (RP) causes CN degeneration and secondary penile fibrosis and smooth muscle cell (SMC) apoptosis. Pentoxifylline (PTX) is a phosphodiesterase inhibitor that further inhibits multiple cytokine pathways involved in nerve degeneration, apoptosis, and fibrosis.Objectives-To evaluate whether PTX enhances erectile function in a rat model of CN injury.Design, Setting and Interventions-Forty male Sprague-Dawley rats underwent CN crush injury and were randomized to oral gavage feeding of phosphate-buffered saline (vehicle) or PTX 25, PTX 50, or PTX 100 mg/kg per day. Ten animals underwent sham surgery and received vehicle treatment. Treatment continued for 28 d, followed by a wash-out period of 72 h. An additional eight rats underwent resection of the major pelvic ganglion (MPG) for tissue culture and examination of direct effects of PTX on neurite sprouting. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.Author contributions: Tom F. Lue had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Financial disclosures: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Maarten Albersen is a fellow of the Research Foundation -Flanders (FWO) and a scholar of the European Society of Surgical Oncology (ESSO), the Federico Foundation, and Belgische Vereniging voor Urologie (BVU), and he received an unrestricted research grant from Bayer Healthcare Belgium. NIH Public AccessAuthor Manuscript Eur Urol. Author manuscript; available in PMC 2012 February 1. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author ManuscriptMeasurements-Intracavernous pressure recording on CN electrostimulation, immunohistologic examination of the penis and the CN distal to the injury site, and length of neurite sprouts in MPG culture.Results-Daily oral gavage feeding of PTX resulted in significant improvement of erectile function compared to vehicle treatment in all treated groups. After treatment with PTX 50 and PTX 100 mg/kg per day, the expression of neuronal nitric oxide synthase in the dorsal penile nerve was significantly higher than in vehicle-treated rats. Furthermore, PTX treatment prevented collagen deposition and S...

show abstract

Section: Discussionmentioning

confidence: 99%

Pentoxifylline Promotes Recovery of Erectile Function in a Rat Model of Postprostatectomy Erectile Dysfunction

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In addition to anti-ischemic and anti- inflammatory effects, pentoxifylline has anti-fibrotic effects that have been investigated in many studies. It has shown great promise as an anti-fibrotic therapy for radiation-induced skin fibrosis, nonalcoholic steatohepatitis, liver fibrosis, radiation-induced lung fibrosis, oral submucous fibrosis, intraperitoneal adhesions, pulmonary sarcoidosis, and corporeal fibrosis [Peyronie's disease] [23–30]. …”

Section: Discussionmentioning

confidence: 99%

Effects of pentoxifylline on renal structure after urethral obstruction in rat: A stereological study

Shirazi¹,

Noorafshan²

2011

cejurol1/2011

View full text Add to dashboard Cite

ObjectiveChronic renal failure due to tubulointerstitial fibrosis is one of complications of lower urinary tract obstruction. Since pentoxifylline is a xanthine derivative that inhibits some inflammatory mediators, we conducted this study to investigate whether pentoxifylline inhibits renal fibrosis in a rat model of partial urethral obstruction (PUO).MethodsAll the rats underwent experimental PUO. Then, the animals were divided randomly into two groups: positive control group and experimental group. The experimental group received pentoxifylline 100 mg/kg per day via oral gavages for 4-weeks. The control group received the same dose of normal saline. After 4-weeks, all the rats underwent left nephrectomy. Kidney volume and weight and fractional and absolute volumes of the glomeruli, tubules, interstitium and vessels were determined with stereological methods. To reduce the workload of reference (kidney) volume estimation, the total kidney volume was determined after estimation of tissue shrinkage on isotropic uniform random histological sections. The total volume (amount) of each renal structure including fibrosis was estimated to avoid the bias conclusion due to relying on volume density alone.ResultsThe absolute volume of interstitial fibrosis was lower in the experimental group (PUO with pentoxifylline treatment) (~84%; p ≤0.006) in comparison with the control group (PUO with no treatment).ConclusionPentoxifylline reduces interstitial renal fibrosis after partial urethral obstruction in rats.

show abstract

“…[1] Clinically, it presents as a palpable penile scar in the flaccid condition, which is associated with penile pain, angulation, and erectile dysfunction. A myriad of medical therapies like pentoxifyllin,[2] colchicine, potassium amino benzoate, vitamin E, tamoxifen, and acetyl-L-carnitine systemically;[3] verapamil, clostridial collagenase, interferon-α-2b, corticosteroids, and hyaluronidase intralesionally,[4] and verapamil gel topically[5] have been used with variable success. We report a case of peyronie's disease treated by oral weekly dexamethsone (5 mg) two consecutive days weekly and cyclophosphamide (50 mg) daily orally.…”

mentioning

confidence: 99%

“…Over the years, various medical and surgical therapies have been used to treat this condition with variable success. [2345]…”

mentioning

confidence: 99%

Peyronie′s disease treated with oral weekly dexamethasone and continuous low-dose cyclophosphamide

Gupta

2014

Indian J Dermatol

View full text Add to dashboard Cite

Therapeutic benefit of pentoxifylline for Peyronie's disease

Cited by 4 publications

References 1 publication

Pentoxifylline Promotes Recovery of Erectile Function in a Rat Model of Postprostatectomy Erectile Dysfunction

Pentoxifylline Promotes Recovery of Erectile Function in a Rat Model of Postprostatectomy Erectile Dysfunction

Effects of pentoxifylline on renal structure after urethral obstruction in rat: A stereological study

Peyronie′s disease treated with oral weekly dexamethasone and continuous low-dose cyclophosphamide

Contact Info

Product

Resources

About